Skip to main content

Table 1 Patient characteristics at erenumab initiation

From: Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension

  P1 P2 P3 P4 P5 P6 P7 Mean (SD)
Age (years) 42 34 46 24 36 25 25 33.1 (8.2)
Duration of IIH (years) 2 2 1 1 4 2 5 2.4 (1.5)
Headache exacerbation at IIH diagnosis +++ +++ +++ +++ +++ +++ +++  
Duration of headaches from resolution of papilloedema to initiation of erenumab (months) 12 3 3 3 24 6 3 7.7 (7.9)
Preventative drug class failure a 4 3 3 4 5 4 3 3.7 (0.8)
Preventative drug class trial b 3 2 1 0 4 1 1 1.7 (1.4)
Migraine family history yes no missing no no yes no  
Migraine prior to IIH yes yes yes no no yes no  
MmsHD 12 months prior 12 20 16 16 14 8 14 14.3 (3.5)
p = 0.778
MmsHD at erenumab initiation 13 17 15 20 14 11 12 14.6 (3.1)
MHD 12 months prior 30 30 30 30 28 30 20 28.3 (3.7)
p = 0.593
MHD at erenumab initiation 30 30 27 30 30 30 25 28.9 (2.0)
Headache severity (NRS) at erenumab initiation 5.7 5.2 7.2 7.3 5.2 4.5 7.1 6.0 (1.2)
Monthly analgesic days at erenumab initiation 2 6 6 20 7 4 12 8.1 (6.1)
HIT-6 score at erenumab initiation 68 65 70 75 66 68 63 67.9 (3.9)
Frisén grade at erenumab initiation (both eyes) 0 0 0 0 0 0 0 0
OCT global average RNFL thickness at Erenumab initiation worst eye (μm) c 118 93 123 113 107 118 103 110.7 (10.4)
BMI at erenumab initiation 31 46.2 35.2 37.3 42.1 29.4 28.8 35.7 (6.6)
IIH characteristics at erenumab initiation B, T B, T B, T B, D, T B, D, T D, T B, T  
Acetazolamide at erenumab initiation no no no no no 500 mg no  
  1. Patient clinical characteristics at erenumab initiation. Monthly values refer to the 30-day pre-treatment period. *, p values indicate changes from the 30-day pre-treatment period prior to erenumab initiation
  2. aFailure defined as any of: inadequate efficacy with appropriate dosing and treatment duration; intolerable adverse effects; contraindications preventing use
  3. bTrial defined as any of: inadequate efficacy with appropriate dosing and treatment duration; intolerable adverse effects
  4. cHeidelberg Engineering SPECTRALIS, Heidelberg, Germany
  5. +++ severe
  6. Abbreviations: P Patient, IIH Idiopathic intracranial hypertension, MmsHD Monthly moderate/severe headache days, MHD Monthly headache days, NRS Numeric Rating Scale (0 = no pain to 10 = worst imaginable pain), HIT-6 Headache impact test-6, BMI Body mass index, B Blurred vision, D double vision, T Tinnitus, V Visual obscurations, OCT Optical coherence tomography, RNFL Retinal nerve fiber layer